Donna H. Ryan MD
Professor Emerita, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LouisianaDonna Ryan is Professor Emerita at Pennington Biomedical in Baton Rouge, LA, USA where she had a 30-year career in clinical research in obesity.
She was an investigator on POUNDS Lost, Look AHEAD, DPP, DASH and many other studies investigating the health benefits of weight loss by various intervention strategies. She was PI of a series of studies for the US Department of Defence which targeted military nutrition. Her personal research targeted improving primary care management of obesity.
Currently, Dr. Ryan serves as Past President of the World Obesity Federation, Co-Chair of the SELECT Steering Committee and member of the Data Safety Monitoring Board for setmelanotide.
She has more than 300 publications and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programs and medical approaches to obesity management.
Disclosures
Dr. Ryan reports the following for the past 24 months (as of Feb 3, 2023):- Advisor/consultant: Altimmune, Amgen, Calibrate, Carmot, Epitomee, Gila, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Wondr Health, Xeno Bioscience, YSOPIA, Zealand
- Speaker’s Bureau: Novo Nordisk
- Stock Options: Epitomee, Calibrate, Roman, Scientific Intake, Xeno Bioscience
- Research: SELECT Steering Committee (Novo Nordisk) and DSMB(2) (Rhythm)
Recent Contributions to PracticeUpdate:
- Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in Individuals With Overweight/Obesity but Without Diabetes
- Effect of Semaglutide on Regression and Progression of Glycemia in Individuals With Overweight/Obesity but Without Diabetes
- Novel Lifestyle Intervention With or Without Meal Replacements at Work Sites
- Bariatric Surgery and Risk of Heart Failure
- Individualizing Therapy for Obesity With Drugs and Devices